Donald Cutlip, MD
Interventional Cardiology · Boston, MANPI 1396777827
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (46.2%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 7 manufacturers reported payments, led by Boston Scientific at 39.9% of the total. 2025 is the largest year on record at $7,600, more than ten times the $149 reported in 2019.
Across 15 payments — averaging $1119.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$7K
- Cordis US CORP.$6K
- Abiomed$2K
- Magenta Medical Inc$2K
- Celonova Biosciences, Inc.$232
- Abbott$104
- plus $89 from 1 others
Across 18 payments — averaging $5018.44 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boston Scientific$72K
- M.a. Med Alliance S.A.$13K
- Abbott$5K
What the payments were for
- Consulting fees$7,75046%
- Speaking & faculty fees$7,60045%
- Travel & lodging$6514%
- Food & beverage$7895%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 4 | $6,703 |
| Cordis US CORP. | 5 | $6,162 |
| Abiomed | 1 | $2,000 |
| Magenta Medical Inc | 1 | $1,500 |
| Celonova Biosciences, Inc. | 2 | $232 |
| Abbott | 1 | $104 |
| Edwards Lifesciences | 1 | $89 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SELUTION SLR PTA$5,600
- Impella$2,000
- SELUTION SLR PTCA$396
- SELUTION SLRPTA$120
- PORTICO$104
How this compares
$16,790 in reported general payments places this provider in the 70th percentile of 128 interventional cardiology providers in Massachusetts.
See all interventional cardiology providers in Massachusetts →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 51 | $69,514 |
| EntrestoSacubitril/Valsartan | 16 | $21,376 |
| Repatha SureclickEvolocumab | 11 | $14,216 |
| Ezetimibe | 42 | $1,987 |
| Metoprolol Succinate | 107 | $1,545 |
| Atorvastatin Calcium | 96 | $1,342 |
| Valsartan | 23 | $1,204 |
| Rosuvastatin Calcium | 27 | $1,163 |
| Torsemide | 25 | $473 |
| Amlodipine Besylate | 63 | $428 |
| Lisinopril | 59 | $357 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 54 | $317 |
| ClopidogrelClopidogrel Bisulfate | 36 | $295 |
| Amiodarone Hcl | 18 | $282 |
| Furosemide | 37 | $240 |
Paid to pharmacies, not to this prescriber.
Other interventional cardiology in Boston
- Eric SecemskyBoston$1.2M
- Darshan DoshiBoston$730K
- Charles GibsonBoston$661K
- Duane PintoBoston$491K
- Robert YehBoston$412K
- Suzanne BaronBoston$274K
- Farouc JafferBoston$213K
- Joseph GarasicBoston$152K
- Pinak ShahBoston$147K
- Douglas DrachmanBoston$132K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.